NEWS
Zylera Pharmaceuticals Announces Trade Launch of RELAMINE
October 30, 2006
Research Triangle Park, North Carolina – October 30, 2006 - Zylera Pharmaceuticals announced today the availability of its novel product, RELAMINE™ (chondroitin 300mg, glucosamine 400mg and primorine 425mg) for the treatment of osteoarthritis.
“The goal of Zylera Pharmaceuticals is to help patients do more than expected,” said Dr. Philip Tabbiner, chief executive officer of Zylera Pharmaceuticals. RELAMINE, a new product for the treatment of osteoarthritis, does just that. RELAMINE reduces joint swelling and helps control the joint pain associated with osteoarthritis and can be used in combination with current treatments for this disease.”
Osteoarthritis is characterized by chronic and often disabling pain and stiffness of one or more joints, particularly those of the fingers, spine, hips, knees and feet. Osteoarthritis is the most common form of arthritis. Arthritis is one of the most prevalent chronic health problems and the nation’s leading cause of disability among Americans over age 15. Over 66 million Americans have this disease which is second to heart disease in causing work disability.
About RELAMINE
RELAMINE™ (chondroitin 300mg, glucosamine 400mg and primorine 425mg) reduces the inflammation of moderate to severe osteoarthritis and its associated pain. Zylera’s approach is to combine two well-known medicines – chondroitin and glucosamine – with its proprietary Cytac™ technology to deliver consistent and reliable relief. Cytac, a novel carbonyl-trapping agent, enables Zylera’s products to react with, or “trap,” toxic carbonyl groups such as aldehydes and ketones that the body produces under conditions of oxidative stress to form less-harmful derivatives that are then eliminated through the kidneys.
About Zylera Pharmaceuticals
Zylera is a specialty pharmaceutical company focused on developing medications that will treat multiple diseases arising within the inflammation and immunosuppressive pathways. Its near-term pipeline includes products for diabetes, elevated cholesterol, osteoporosis, and osteoarthritis, utilizing proprietary and patented chemical entities designed to restore key metabolic processes. Chief among these is Cytac, a carbonyl-trapping agent. Zylera is based in Research Triangle Park, NC.
FOR IMMEDIATE RELEASE Media Contact:
Susan Preston, TRx Pharma
Office: (919) 313-3568